Gilead Sciences Inc (GILD)

Current ratio

Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Total current assets US$ in thousands 18,000,000 14,779,000 12,317,000 14,041,000 16,454,000 16,013,000 15,411,000 14,372,000 15,227,000 13,898,000 13,175,000 13,214,000 15,056,000 14,200,000 14,498,000 13,166,000 15,816,000 31,915,000 26,351,000 30,242,000
Total current liabilities US$ in thousands 12,004,000 11,725,000 10,781,000 13,015,000 11,280,000 11,945,000 13,964,000 10,528,000 11,237,000 10,423,000 9,220,000 8,558,000 11,610,000 10,245,000 10,214,000 9,705,000 11,397,000 9,509,000 10,564,000 8,879,000
Current ratio 1.50 1.26 1.14 1.08 1.46 1.34 1.10 1.37 1.36 1.33 1.43 1.54 1.30 1.39 1.42 1.36 1.39 3.36 2.49 3.41

December 31, 2024 calculation

Current ratio = Total current assets ÷ Total current liabilities
= $18,000,000K ÷ $12,004,000K
= 1.50

The current ratio of Gilead Sciences Inc has shown fluctuations over the period from March 31, 2020, to December 31, 2024. The current ratio measures the company's ability to meet its short-term obligations with its current assets.

Gilead's current ratio was relatively stable and strong at the beginning of the period, standing at 3.41 on March 31, 2020. However, there was a notable drop in the ratio to 1.39 by December 31, 2020, indicating a potential liquidity concern as the ratio fell below the ideal level of 2.

The trend continued to decline through the first half of 2021, reaching 1.36 on March 31, 2021. There was a slight improvement in the current ratio in the later part of 2021, but it remained below 2.

Throughout 2022 and the first half of 2023, Gilead's current ratio hovered around 1.40, showing some stability but still indicating a weaker liquidity position compared to the earlier years.

However, in the latter part of 2023 and 2024, the current ratio experienced significant fluctuations, dropping to as low as 1.08 on March 31, 2024, which could be a cause for concern regarding the company's ability to cover its short-term obligations.

Overall, the declining trend in Gilead's current ratio from the initial strong levels indicates a potential liquidity risk that investors and stakeholders may need to monitor closely.


See also:

Gilead Sciences Inc Current Ratio (Quarterly Data)